[Study on three patients with malignant glioma showing tumor reduction during maintenance therapy with MCNU].
Tumor regression occurred in three of 19 patients (15.8%) with malignant glioma during maintenance therapy using MCNU. In two patients, the tumor reduced 5 and 8 months after the initial treatment, respectively. In the remaining patient, though the maintenance therapy was interrupted for a while and consequently the tumor size increased, readministration of MCNU reduced the tumor size two months later. Therefore, since the antitumor activity of MCNU against malignant glioma seems to require a certain time depending on the case, it is recommended that MCNU be given as maintenance therapy for at least half a year.
Kiya
K
K
Dept. of Neurosurgery, Hiroshima University School of Medicine.
Uozumi
T
T
Kurisu
K
K
Mikami
T
T
Sugiyama
K
K
Monden
S
S
Maeda
H
H
Matsuoka
T
T
Matsuda
Y
Y
Harada
K
K
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001254:Astrocytoma / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D001932:Brain Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D002675:Child, Preschool; D005260:Female; D006801:Humans; D008297:Male; D009607:Nitrosourea Compounds / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed
D000970:Antineoplastic Agents; D009607:Nitrosourea Compounds; C020766:ranimustine